Muhammad Ilham Fauzan, Besut Daryanto, Taufiq Nur Budaya, Moh Anfasa Giffari Makkaraka, Muhammad Fakhri, Ilham Akbar Rahman
{"title":"有前途的选择性α-1受体阻滞剂西洛多辛作为治疗早泄的新策略及其药物不良反应分析:随机对照试验的系统回顾和荟萃分析。","authors":"Muhammad Ilham Fauzan, Besut Daryanto, Taufiq Nur Budaya, Moh Anfasa Giffari Makkaraka, Muhammad Fakhri, Ilham Akbar Rahman","doi":"10.4081/aiua.2024.12984","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Premature Ejaculation (PE) occurs in 31% of men aged 18-59 years, leading to disappointment and avoidance of sexual relations. The current guideline of treatment for PE is Dapoxetine, which possesses several adverse effects causing the limitation of its long-term use. Silodosin, an alpha-1 blocker, has been proposed as a new option for treating PE due to its minimal side effects. Therefore, our study aims to assess the efficacy of silodosin in treating PE.</p><p><strong>Materials and methods: </strong>This systematic review and meta-analysis was in accordance with Cochrane Handbook guidelines. Comprehensive literature search was conducted in several databases including PubMed, ScienceDirect, and Cochrane Central Register of Controlled Trials. The studies were included if they met the following criteria: (1) Involving premature ejaculation patients; (2) Intervention using silodosin; (3) Comparing placebo or other therapies for PE (4) Outcome includes the Intravaginal Ejaculation Latency Time (IELT) and reported adverse events related to the therapy. Study quality was assessed using Cochrane risk-of-bias criteria. Statistical analysis in this study was performed using Review Manager 5.4 Results: A total of four studies were included in this meta-analysis. Our study showed that patients who received silodosin had a significantly longer IELT compared to control (MD: 132.54, 95% CI 51.51-213.57, p < 0.001). However, patient treated with silodosin also possessed significantly higher risk of adverse event for developing reduced semen ejaculation (OR 10.79, 95% CI 3.46-33.67, p < 0.0001).</p><p><strong>Conclusions: </strong>Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation.</p>","PeriodicalId":46900,"journal":{"name":"Archivio Italiano di Urologia e Andrologia","volume":"96 4","pages":"12984"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trials.\",\"authors\":\"Muhammad Ilham Fauzan, Besut Daryanto, Taufiq Nur Budaya, Moh Anfasa Giffari Makkaraka, Muhammad Fakhri, Ilham Akbar Rahman\",\"doi\":\"10.4081/aiua.2024.12984\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction and objectives: </strong>Premature Ejaculation (PE) occurs in 31% of men aged 18-59 years, leading to disappointment and avoidance of sexual relations. The current guideline of treatment for PE is Dapoxetine, which possesses several adverse effects causing the limitation of its long-term use. Silodosin, an alpha-1 blocker, has been proposed as a new option for treating PE due to its minimal side effects. Therefore, our study aims to assess the efficacy of silodosin in treating PE.</p><p><strong>Materials and methods: </strong>This systematic review and meta-analysis was in accordance with Cochrane Handbook guidelines. Comprehensive literature search was conducted in several databases including PubMed, ScienceDirect, and Cochrane Central Register of Controlled Trials. The studies were included if they met the following criteria: (1) Involving premature ejaculation patients; (2) Intervention using silodosin; (3) Comparing placebo or other therapies for PE (4) Outcome includes the Intravaginal Ejaculation Latency Time (IELT) and reported adverse events related to the therapy. Study quality was assessed using Cochrane risk-of-bias criteria. Statistical analysis in this study was performed using Review Manager 5.4 Results: A total of four studies were included in this meta-analysis. Our study showed that patients who received silodosin had a significantly longer IELT compared to control (MD: 132.54, 95% CI 51.51-213.57, p < 0.001). However, patient treated with silodosin also possessed significantly higher risk of adverse event for developing reduced semen ejaculation (OR 10.79, 95% CI 3.46-33.67, p < 0.0001).</p><p><strong>Conclusions: </strong>Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation.</p>\",\"PeriodicalId\":46900,\"journal\":{\"name\":\"Archivio Italiano di Urologia e Andrologia\",\"volume\":\"96 4\",\"pages\":\"12984\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archivio Italiano di Urologia e Andrologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/aiua.2024.12984\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivio Italiano di Urologia e Andrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/aiua.2024.12984","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介和目的:在18-59岁的男性中,有31%的人发生早泄,导致失望和避免性关系。目前PE的治疗指南是达泊西汀,它有一些不良反应,限制了它的长期使用。西洛多辛(Silodosin)是一种α -1受体阻滞剂,由于其副作用最小,已被提议作为治疗PE的新选择。因此,我们的研究旨在评估西洛多辛治疗PE的疗效。材料和方法:本系统综述和荟萃分析符合Cochrane手册指南。在PubMed、ScienceDirect、Cochrane Central Register of Controlled Trials等数据库中进行了全面的文献检索。符合以下标准的研究被纳入:(1)涉及早泄患者;(2)西洛多辛干预;(4)结果包括阴道内射精潜伏期(ielts)和报告的与治疗相关的不良事件。采用Cochrane风险偏倚标准评估研究质量。本研究采用Review Manager 5.4进行统计分析。结果:本荟萃分析共纳入4项研究。我们的研究显示,与对照组相比,接受西洛多辛治疗的患者的雅思考试时间明显更长(MD: 132.54, 95% CI 51.51-213.57, p < 0.001)。然而,接受西洛多辛治疗的患者出现射精减少的不良事件风险也明显更高(OR 10.79, 95% CI 3.46-33.67, p < 0.0001)。结论:西洛多辛显著提高雅思成绩。然而,它也减少了射精作为其药物的副作用。这一结果支持临床使用西洛多辛作为早泄的替代治疗。
Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trials.
Introduction and objectives: Premature Ejaculation (PE) occurs in 31% of men aged 18-59 years, leading to disappointment and avoidance of sexual relations. The current guideline of treatment for PE is Dapoxetine, which possesses several adverse effects causing the limitation of its long-term use. Silodosin, an alpha-1 blocker, has been proposed as a new option for treating PE due to its minimal side effects. Therefore, our study aims to assess the efficacy of silodosin in treating PE.
Materials and methods: This systematic review and meta-analysis was in accordance with Cochrane Handbook guidelines. Comprehensive literature search was conducted in several databases including PubMed, ScienceDirect, and Cochrane Central Register of Controlled Trials. The studies were included if they met the following criteria: (1) Involving premature ejaculation patients; (2) Intervention using silodosin; (3) Comparing placebo or other therapies for PE (4) Outcome includes the Intravaginal Ejaculation Latency Time (IELT) and reported adverse events related to the therapy. Study quality was assessed using Cochrane risk-of-bias criteria. Statistical analysis in this study was performed using Review Manager 5.4 Results: A total of four studies were included in this meta-analysis. Our study showed that patients who received silodosin had a significantly longer IELT compared to control (MD: 132.54, 95% CI 51.51-213.57, p < 0.001). However, patient treated with silodosin also possessed significantly higher risk of adverse event for developing reduced semen ejaculation (OR 10.79, 95% CI 3.46-33.67, p < 0.0001).
Conclusions: Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation.